Navigation Links
Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA)
Date:3/15/2012

rticipate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21582928.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21582928.

About Esbriet®

Esbriet® (pirfenidone) is an orally active drug, indicated in adults for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  The anti-fibrotic acting pirfenidone inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key role in fibrosis.  It also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.

On February 28, 2011, the European Commission (EC) granted marketing authorization for Esbriet® in adults for the treatment of mild to moderate IPF.  The approval authorizes marketing of Esbriet® in all 27 EU member states.  Esbriet® has since been approved for marketing in Norway and Iceland.  In addition to Germany, Esbriet® is commercially available in Austria, Norway, Denmark and Luxembourg.

Since 2008, pirfenidone has been marketed in Japan as Pirespa® by Shionogi & Co. Ltd.  In the United States, pirfenidone is currently being evaluated for the treatment of IPF in another clinical trial and is not yet approved by the FDA for this indication.

About IPF

Idiopathic pulmonary fibrosis
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. New Data Demonstrate Longer-Term Safety Profile of Esbriet®
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
5. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
6. New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
7. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
8. Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program
9. Sleep Breathing Machine Shows Clear Benefits in Children with Sleep Apnea
10. Study Highlights CyberKnife SBRT Benefits for Treatment of Central Lung Tumors
11. Recent Study Reveals Benefits to Women From DHEA Hormone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Calif. , Aug. 28, 2014  In anticipation of ... infographic is being made available for the first time. ... Diego offers a snapshot of ... Highlighting everything from the latest employment statistics to ... made San Diego such a vital ...
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek,Pharmaceuticals Corporation ... preclinical animal data showing that the,administration of a ... on the survival of certain brain,cells following a ... the,repair of damaged DNA via the activation and ...
... study appearing in the March,22 New England Journal ... Healths National Institute of Arthritis and,Musculoskeletal and Skin ... gene and the inflammatory skin,condition vitiligo, as well ... is a chronic condition in which melanocytes (the ...
Cached Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... 2014 Career Step, an online provider ... new video designed to help students and career seekers ... billing field. The video details what medical coders and ... professionals, and the education requirements for entering this field. ... often overlooked when people are considering a career in ...
(Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
(Date:8/28/2014)... When David Gergen, President of ... Mark Brnovich, was asked to publicly support Mr. Brnovich ... Attorney General seat in the State of Arizona, Mr. ... of Cardinal Hall of Fame wide receiver Roy Green ... Mark Walczak. Green, Kennard and Walczak are members of ...
(Date:8/28/2014)... Farmington, New York (PRWEB) August 29, 2014 ... Autumn as they will be traveling around the country ... with a final show in November. The New Energy ... exhibit sharing their timber frame design and build expertise, ... addition, Drake Ambrosino , New Energy Works’ Mid-West ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3
... ... recent launch of accounts on the popular social networking sites, Facebook, Twitter, and LinkedIn. ... Las Vegas, ... consultations, diagnoses, prescriptions, and doctors, excuses for work and school, expands its outreach to ...
... SEATTLE, Aug. 27 IDRI (Infectious Disease Research ... in Sudan to test its leishmaniasis vaccine candidate for ... complication of visceral leishmaniasis (VL) which is observed in ... predominantly affecting children. This trial reflects IDRI,s commitment to ...
... PRINCETON, N.J., Aug. 27 More than 160 ... are coming together at educational summits sponsored this fall by ... Continuing Education (CBCE). For the fifth year, the Inhibitor Education ... professionals and fellow patients to address pertinent topics such as ...
... rates similar to those with deceased donor transplant organs, ... People with kidney disease may do just as well ... from a deceased donor, new research has found. , ... 1,239 patients who had either received a kidney transplant ...
... Japan, Aug. 27 Hisamitsu Pharmaceutical Co., Inc. (TSE: ... completion of the tender offer for all outstanding shares of Noven ... price per share of $16.50. The subsequent offering period expired ... 2009 and was not extended. , , ...
... , MAPLE GROVE, Minn., Aug. 27 NeuroVasx, Inc., ... hemorrhagic and ischemic stroke, announced today that it has received approval ... Canada,s Therapeutic Products Directorate. In addition to Canadian regulatory approval, ... , Eric B. Timko, President and Chief Executive ...
Cached Medicine News:Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 2Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Medicine Products: